Matthew S. Davids, MD, Associate Director, Dana-Farber Cancer Institute Center for Chronic Lymphocytic Leukemia, discusses a multicenter study of ibrutinib (Imbruvica) plus FCR as a frontline therapy for younger patients with chronic lymphocytic leukemia (CLL). <br />
Denise Yardley, MD, Senior Investigator, Sarah Cannon Research Institute, offers advice to community oncologists on managing patients.
Maria Svensson, MD, Lund University, discusses associations of PD-1 and PD-L1 expression with mismatch repair status and prognosis in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma.<br />
Anna Sureda, MD, PhD, Head of the Clinical Hematology Service at the Institut Català d'Oncologia – Hospitalet de Llobregat in Barcelona, discusses the phase III ECHELON-1 study exploring brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (A+AVD) versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma.
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses a randomized phase II trial to evaluate dosing strategies for regorafenib (Stivarga) in patients with refractory metastatic colorectal cancer.
Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses advances in the treatment of metastatic renal cell carcinoma (RCC).
Cristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses targeted therapies for <em>BRCA</em>1/2-mutated tumors.
Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the results of a study investigating entrectinib in patients with metastatic pancreatic cancer who harbor <em>NTRK</em> and <em>ROS1</em> fusions.
Phyllis McKiernan, a nurse practitioner at John Theurer Cancer Center, Hackensack Medical Center, discusses a study of outcomes of autologous stem cell transplantation in very elderly patients with multiple myeloma.
Matthew Goetz, MD, professor of oncology and pharmacology, Mayo Clinic, discusses a secondary analysis of the MONARCH 1 and MONARCH 2 clinical trials in breast cancer.
Emanuela Palmerini, MD, Prometeo Laboratory: Clinical and Experimental Research Contract, Chemotherapy for Rare Musculoskeletal Tumors Department, Instituto Ortopedico Rizzoli, discusses optimal patient selection for denosumab (Xgeva) in patients with giant cell tumor of bone.
Helmut Schaider, MD, associate professor, Dermatology Research Centre, The University of Queensland, Australia, discusses drug resistance in melanoma.<br />
Saad Z. Usmani, MD, Chief of the Plasma Cell Disorders Program, Levine Cancer Institute/Carolinas HealthCare System, discusses the MMprofiler in multiple myeloma.
Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, discusses a randomized controlled phase II study to evaluate secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.
Roger Stupp, MD, discusses final results of a randomized, multi-center, phase III trial investigating tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma.
Charles Coombes, MD, professor of medical oncology, Imperial College London, discusses a study of celecoxib versus placebo in primary breast cancer patients.
Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significance of the PROTECT study in patients with localized prostate cancer.<br /> ​
Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses a phase I, open-label, multicenter trial of oral azacitidine (CC-486) plus R-CHOP in patients with high-risk, previously untreated diffuse large B-cell lymphoma, grade 3B follicular lymphoma, or transformed lymphoma.
William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the use of abiraterone and docetaxel in patients with metastatic castration-resistant prostate cancer.
Prithviraj Bose, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses a study exploring sotatercept (ACE-011) alone and in combination with ruxolitinib (Jakafi) in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia.
Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Feinberg School of Medicine at Northwestern University, discusses the importance of identifying and treating patients with follicular lymphoma (FL) who experience progression of their disease.
Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing clinical trials in the <em>BRAF</em>-mutant colorectal cancer patient population.
Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses sequencing immunotherapy agents in advanced-stage lung cancer.<br />
Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses recent chemotherapy and immunotherapy advances in the treatment of squamous cell lung cancer.
Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses areas she believes will be the focus of future research in pancreatic cancer.
H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute at Swedish Medical Center, discusses how he treats patients with advanced lung cancer who do not have actionable oncogenic drivers.
Andrew L. Pecora, MD, President of the Physician Services Division and Chief Innovation Officer at Hackensack Meridian Health, discusses preliminary safety and efficacy data for combined checkpoint inhibition with ipilimumab (Yervoy) and nivolumab (Opdivo) as consolidation therapy following autologous stem cell transplant in patients with multiple myeloma and non-Hodkin lymphoma.
Hope S. Rugo, MD, a medical oncologist and Director of the Breast Oncology Clinical Trials Program at University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses 5-year follow-up data from the CALGB 40502//NCCTG N063H study, which was a randomized phase III trial of weekly paclitaxel (Abraxane) compared with nab-paclitaxel or ixabepilone (Ixempra) with bevacizumab (Avastin) as first-line chemotherapy for locally recurrent or metastatic breast cancer.
John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the progress that has been made with immunotherapy in the treatment of colorectal cancer.
Anas Younes, MD, Chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the interim analysis of a study exploring the safety and efficacy of atezolizumab (Tecentriq) in combination with obinutuzumab (Gazya) and bendamustine in patients with previously untreated follicular lymphoma.